(2R)-2-吡咯烷基乙酸盐酸盐(1:1) | 439918-59-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (2R)-2-吡咯烷基乙酸盐酸盐(1:1)
• 中文别名: (2R)-2-吡咯烷乙酸盐酸盐；2-吡咯烷乙酸,盐酸(1:1),(2R)
• 英文名称: (R)-β-Pro hydrochloride
• 英文别名: (2R)-pyrrolidin-2-ylacetic acid hydrochloride；(R)-2-(pyrrolidin-2-yl)acetic acid hydrochloride；(R)-2-(pyrrolidin-2-yl)acetic acid hydrochloride salt；2-[(2R)-pyrrolidin-2-yl]acetic acid;hydrochloride
• CAS: 439918-59-9
• 化学式: C₆H₁₁NO₂*ClH
• 分子量: 165.62
• InChiKey: VQDACVOAOJQTPR-NUBCRITNSA-N

物化性质

• 熔点：
  195-197℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.63
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

反应信息

• 作为反应物：
  描述：

  (2R)-2-吡咯烷基乙酸盐酸盐(1:1) 在 盐酸 、 palladium diacetate 、 caesium carbonate 、 2-(二叔丁基膦)联苯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 19.0h， 生成 (R)-ethyl 2-(1-(4-(2,4-dichlorobenzyloxy)phenyl)pyrrolidin-2-yl)acetate
  参考文献：
  名称：

  Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

  摘要：

  A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding K-i and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both G(q)-coupled intracellular Ca2+ flux and G(s)-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

  DOI：

  10.1021/acs.jmedchem.6b01559
• 作为产物：
  描述：

  (R)-2-(氰基甲基)吡咯烷-1-甲酸叔丁酯 在 盐酸 、 水 作用下， 以 溶剂黄146 为溶剂， 反应 6.0h， 以83%的产率得到(2R)-2-吡咯烷基乙酸盐酸盐(1:1)
  参考文献：
  名称：

  SUBSTITUTED BENZHYDRYLETHERS

  摘要：

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。

  公开号：

  US20090203763A1

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE UTILISABLES EN TANT QUE MODULATEURS DE L'ACTIVITÉ TNF
  申请人：UCB PHARMA SA

  公开号：WO2014009295A1

  公开（公告）日：2014-01-16

  A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列式(I)的咪唑并[1,2-a]吡啶衍生物，作为人类TNFa活性的有效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经学和神经退行性疾病；疼痛和伤害感知性疾病；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• [EN] N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-HÉTÉROARYLALKYLE-2-(HÉTÉROCYCLYLE ET HÉTÉROCYCLYLMÉTHYLE) ACÉTAMIDE UTILISÉS EN TANT QU'AGONISTES DE SSTR4
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021202781A1

  公开（公告）日：2021-10-07

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

  揭示了Formula 1的化合物及其药用盐，其中L、n、R1、R2、R6、R7、R8、R9、R10、X3、X4和X5在说明书中有定义。本公开还涉及制备Formula 1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与SSTR4相关的疾病、疾患和症状的用途。
• [EN] FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRROLEDICARBOXAMIDES FUSIONNÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013113860A1

  公开（公告）日：2013-08-08

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及公式（I）中的融合吡咯二羧酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式（I）化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是心房心律失常，如心房颤动或心房扑动，以及呼吸系统疾病，特别是与睡眠相关的呼吸系统疾病，如睡眠呼吸暂停症等。
• SUBSTITUTED PYRIMIDODIAZEPINES
  申请人：Chen Shaoqing

  公开号：US20080234255A1

  公开（公告）日：2008-09-25

  The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas.

  本发明提供了公式I的PLK1抑制剂化合物：用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的制剂可能对实体肿瘤，如乳腺、结肠、肺和前列腺肿瘤以及其他肿瘤性疾病，如非何杰金淋巴瘤的治疗或控制有用。
• Substituted pyrimidodiazepines
  申请人：Hoffman-La Roche Inc.

  公开号：US07517873B2

  公开（公告）日：2009-04-14

  The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas.

  本发明提供了公式I的PLK1抑制剂化合物：用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的制剂可能有用于治疗或控制实体肿瘤，例如乳腺癌，结肠癌，肺癌和前列腺癌以及其他肿瘤疾病，如非何杰金淋巴瘤。